logo

ILMN

Illumina·NASDAQ
--
--(--)
--
--(--)

ILMN fundamentals

Illumina (ILMN) released its earnings on Feb 5, 2026: revenue was 1.16B (YoY +4.98%), beat estimates; EPS was 1.35 (YoY +42.11%), beat estimates.
Revenue / YoY
1.16B
+4.98%
EPS / YoY
1.35
+42.11%
Report date
Feb 5, 2026
ILMN Earnings Call Summary for Q4,2025
  • Revenue Growth: Ex-China revenue up 2% in 2025, Q4 clinical consumables +20% ex-China.
  • Strategic Expansion: Acquired SomaLogic for proteomics, launched BioInsight for drug discovery.
  • Financial Strength: Q4 non-GAAP EPS $1.35 (+42%), 2026 EPS guidance $5.05-5.20.
  • Instrument Momentum: 100+ NovaSeq X placements in Q4, 2026 target 200-240.
  • China Risks: 2026 China sales $210-220M, 1pt headwind to growth.
  • Multiomics Pipeline: Spatial transcriptomics and constellation-read tech launching H1 2026.
EPS
Revenue

Revenue & Expenses

ILMN has released its 2025 Q4 earnings report, with revenue of 1.16B, reflecting a YoY change of 4.98%, and net profit of 334.00M, showing a YoY change of 78.61%. The Sankey diagram below clearly presents ILMN's revenue sources and cost distribution.

Key Indicators

Illumina (ILMN) key financial stats and ratios, covering profitability, financial health, and leverage.
Illumina (ILMN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Illumina (ILMN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Illumina (ILMN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Illumina (ILMN) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Illumina (ILMN) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield